サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1678770

糖尿病治療薬・機器の世界市場（2025年～2033年）

Global Diabetes Care Drugs & Devices Market - 2025-2033

出版日
ページ情報
英文 179 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
糖尿病治療薬・機器の世界市場（2025年～2033年）
出版日: 2025年03月11日
発行: DataM Intelligence
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の糖尿病治療薬・機器の市場規模は、2024年に1,198億6,000万米ドルに達し、2033年には2,444億6,000万米ドルに達すると予測され、予測期間2025年～2033年のCAGRは8.3%で成長する見込みです。

糖尿病治療薬・機器は、血糖値が高いことを特徴とする慢性代謝疾患である糖尿病の管理、モニタリング、コントロールを支援するために設計された医薬品治療と医療機器を指します。これらの医薬品や医療機器は、心血管疾患、神経障害、腎症、網膜症などの糖尿病関連合併症の予防に重要な役割を果たしています。

糖尿病治療薬は、インスリンの分泌を促進したり、インスリン感受性を改善したり、グルコースの吸収を抑えたりすることで、血糖値の調節を助ける薬です。これらの薬剤は、作用機序によって様々なクラスに分類されます。糖尿病治療機器は、モニタリング、治療管理、糖尿病の効果的な管理を支援する医療用具および機器です。これらの機器は、糖尿病管理の正確性、利便性、患者のコンプライアンスを向上させます。

糖尿病治療薬・機器市場は、世界の糖尿病有病率の増加と糖尿病治療薬・機器の進歩により、大きな成長を遂げています。持続グルコース・モニタリング・システム、インスリン・ポンプ、スマート・インスリン・ペンの革新は糖尿病管理を強化し、これらの機器の採用拡大につながりました。モバイル・アプリケーションやウェアラブル技術などのデジタル・ヘルス・ソリューションの統合は、市場の成長をさらに促進しています。

例えば、2024年9月、Senseonics Holdings, Inc.とAscensia Diabetes Careは、18歳以上の1型および2型糖尿病患者向けの次世代CGMシステムEversense 365の米国食品医薬品局（FDA）認可を取得しました。エバーセンス365は、世界初の1年間CGMシステムであり、糖尿病技術と管理における重要なブレークスルーとなります。

市場力学：

促進要因と抑制要因

糖尿病有病率の上昇

糖尿病有病率の上昇が糖尿病治療薬・機器市場の成長を大きく牽引しており、予測期間中も市場の牽引役となることが予想されます。糖尿病の世界の有病率は、ライフスタイルの変化、人口の高齢化、肥満率の上昇により急上昇しています。このような症例の急増は、糖尿病治療薬やケア機器に対する需要の増加を生み出しています。

例えば、国際糖尿病連合によると、2021年には5億3,660万人の成人（20～79歳）が糖尿病と共存しています。この数は、2030年には6億4,280万人、2045年には7億8,370万人に増加すると予測されています。成人の糖尿病患者の4人に3人以上が低・中所得国に住んでいます。このような有病率の増加は、糖尿病治療薬や治療機器の緊急の必要性を浮き彫りにしています。

糖尿病が進行すると、患者は血糖値を管理するために定期的なモニタリングと一貫した薬物療法を必要とします。このため、SMBGシステム、持続グルコースモニターなどの血糖値モニタリング機器、インスリンポンプ、ペンなどのインスリンデリバリー機器、糖尿病治療薬インスリン、経口血糖降下薬など、より良い糖尿病管理のための需要が増加しています。需要の高まりに加え、市場企業は常にイノベーションに注力し、需要を満たす製品を発売しています。

例えば、2024年8月、Insulet Corporationは、画期的なOmnipod 5 Automated Insulin Delivery System（Omnipod 5）が米国で2型糖尿病患者（18歳以上）に使用できることを承認しました。

さらに、アストラゼネカは2024年6月、10歳以上の小児2型糖尿病（T2D）患者の血糖コントロールを改善するファルキシガ（一般名：ダパグリフロジン）の米国食品医薬品局（FDA）の承認を取得しました。FDAの承認は、小児T2NOW第III相試験の良好な結果に基づいています。ファルキシガは、米国において、成人T2D患者を対象に、食事療法と運動療法の補助として血糖コントロールを改善する薬剤として承認されています。

高額な糖尿病治療機器

持続血糖モニター（CGM）やインスリンポンプなどの先進的な糖尿病治療機器は、機器自体の初期費用を除いて、センサーやメンテナンスのためにどこまでも高額な費用がかかることがあります。このような高額なコストは、特にこれらの先進技術が手の届かないものと考えられている開発途上地域での普及を制限しています。

例えば、国立衛生研究所によると、CGMのコストは、機器のコストを加えると大幅に相殺され、12ヶ月のフォローアップ期間中の平均は4,431米ドルであるのに対し、血糖モニターは319米ドルです。さらに、Dexcom G6トランスミッタは、90日間持続する装置1台で保険なしで366米ドルです。Dexcom G6 CGMシステムは、非スマートフォンユーザー用の受信機（540米ドル）と互換性のある携帯電話を除くと、年間約8,000米ドルの自己負担となります。

目次

第1章 市場イントロダクションと範囲

  • レポートの目的
  • 調査のカバー範囲と定義
  • 調査の対象範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • スニペット：製品タイプ別
  • スニペット：用途別
  • スニペット：エンドユーザー別
  • スニペット：地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • 糖尿病の罹患率の上昇
      • 糖尿病治療機器の進歩
    • 抑制要因
      • 糖尿病ケア機器の高コスト
      • 糖尿病治療薬に伴う副作用
    • 機会
      • 糖尿病用ウェアラブル機器とアプリの進歩
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名な企業
    • 最大の販売ブランドを持つ確立されたリーダー
    • 確立された製品を持つ市場リーダー
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の研究
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学
  • キーオピニオンリーダー
  • パイプライン分析

第5章 糖尿病治療薬・機器市場：製品タイプ

  • 糖尿病機器
    • 血糖値モニタリング装置
      • 持続血糖測定装置
      • 自己監視機器
      • 血糖値測定器
      • テストストリップ
      • ランセット
    • インスリン投与装置
      • インスリンポンプ
      • インスリンペン
      • インスリン注射器
      • その他
  • 糖尿病治療薬
    • インスリン
      • 遅効性インスリン
      • 中間型インスリン
      • 速効性インスリン
      • その他
    • 経口糖尿病治療薬
      • ビグアナイド
      • スルホニル尿素
      • チアゾリジンジオン
      • アルファグルコシダーゼ阻害剤
      • ジペプチジルペプチダーゼ-4（DPP-4）阻害剤
      • ナトリウム-グルコース共輸送体-2（SGLT2）阻害剤
      • その他
    • インスリン以外の注射薬
      • グルカゴン様ペプチド-1（GLP-1）受容体作動薬
      • アミリン類似体
    • 併用薬
    • その他

第6章 糖尿病治療薬・機器市場：用途別

  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病
  • 前糖尿病

第7章 糖尿病治療薬・機器市場：エンドユーザー別

  • 病院
  • 専門クリニック
  • 在宅ケア環境
  • 診断センター
  • その他

第8章 糖尿病治療薬・機器市場：地域別の市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要な市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • F. Hoffmann-La Roche Ltd.
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • Abbott Laboratories
  • Medtronic plc
  • Terumo Corporation
  • B. Braun SE
  • Merck & Co., Inc.
  • Novo Nordisk A/S.
  • Eli Lilly and Company
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Insulet Corporation

第11章 前提条件と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証とバリデーション

第12章 付録

目次
Product Code: MD9241

The global diabetes care drugs & devices market reached US$ 119.86 billion in 2024 and is expected to reach US$ 244.46 billion by 2033, growing at a CAGR of 8.3% during the forecast period 2025-2033.

Diabetes care drugs & devices refer to the pharmaceutical treatments and medical devices designed to help manage, monitor and control diabetes, a chronic metabolic disorder characterized by high blood glucose levels. These drugs and devices play a crucial role in preventing diabetes-related complications such as cardiovascular diseases, neuropathy, nephropathy and retinopathy.

Diabetes care drugs are medications that help regulate blood sugar levels by enhancing insulin production, improving insulin sensitivity, or reducing glucose absorption. These drugs are categorized into various classes based on their mechanism of action. Diabetes care devices are medical tools and equipment that assist in monitoring, administering treatments, and managing diabetes effectively. These devices improve accuracy, convenience, and patient compliance in diabetes management.

The diabetes care drugs and devices market is experiencing significant growth, driven by the increasing prevalence of diabetes worldwide and advancements in diabetes care drugs and devices. Innovations in continuous glucose monitoring systems, insulin pumps, and smart insulin pens have enhanced diabetes management, leading to increased adoption of these devices. Integrating digital health solutions, such as mobile applications and wearable technology, has further propelled market growth.

For instance, in September 2024, Senseonics Holdings, Inc. and Ascensia Diabetes Care received the U.S. Food and Drug Administration (FDA) clearance for the next-generation Eversense 365 CGM system for people with Type 1 and Type 2 diabetes aged 18 years and older. Eversense 365 is the world's first One-year CGM system, representing a significant breakthrough in diabetes technology and management.

Market Dynamics: Drivers & Restraints

Rising prevalence of diabetes

The rising prevalence of diabetes is significantly driving the growth of the diabetes care drugs and devices market and is expected to continue driving the market over the forecast period. The global prevalence of diabetes is rising sharply due to lifestyle changes, aging populations, and rising obesity rates. This surge in cases creates a higher demand for diabetes drugs and care devices.

For instance, according to the International Diabetes Federation, in 2021, 536.6 million adults (20-79 years) are living with diabetes i.e., 1 in 10 people. This number is predicted to rise to 642.8 million by 2030 and 783.7 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries. This escalating prevalence highlights the urgent need for diabetes care drugs and devices.

As diabetes progresses, patients require regular monitoring and consistent medication to manage their blood glucose levels. This increases demand for blood glucose monitoring devices such as SMBG systems, continuous glucose monitors, insulin delivery devices such as insulin pumps, pens and diabetes drugs insulin, oral hypoglycemics for better diabetes management. In addition to the rising demand, market players are constantly focused on innovations and launching products that meet the demand.

For instance, in August 2024, Insulet Corporation cleared that its groundbreaking Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now indicated for use by people with type 2 diabetes (ages 18 years and older) in the U.S., making it the first and only AID system FDA-cleared for both type 1 and type 2 diabetes management.

Additionally, in June 2024, AstraZeneca cleared the US Food and Drug Administration (FDA) approval for Farxiga (dapagliflozin) to improve glycaemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older. The FDA approval was based on positive results from the pediatric T2NOW Phase III trial. Farxiga was previously approved in the US in adults with T2D as an adjunct to diet and exercise to improve glycaemic control.

High cost of diabetes care devices

Advanced diabetes care devices such as continuous glucose monitors (CGMs) and insulin pumps can cost anywhere high for sensors and maintenance, not including the upfront costs of the devices themselves. Such high costs limit their adoption, especially in developing regions where these advanced technologies are considered unaffordable.

For instance, according to the National Institute of Health, the costs of CGM are substantially offset if device costs are added, with an average of $4,431 during the 12-month follow-up versus $319 for blood glucose monitor. Additionally, a Dexcom G6 transmitter costs $366 without insurance for one device that lasts 90 days. The Dexcom G6 CGM system can cost around $8,000 annually out-of-pocket, excluding a receiver for non-smartphone users ($540) and a compatible phone.

Segment Analysis

The global diabetes care drugs & devices market is segmented based on product type, application, end-user and region.

The diabetes devices in the product type segment are expected to be the fastest growing segment of diabetes care drugs & devices market

The demand for blood glucose monitoring devices including both self-monitoring blood glucose (SMBG) systems and continuous glucose monitoring (CGM) systems has significantly increased as patients and healthcare providers seek better, more accurate ways to manage diabetes. Thus, rising demand drives the market players to launch advanced devices. For instance, in August 2024, Medtronic plc cleared the U.S. Food and Drug Administration (FDA) approval for its Simplera continuous glucose monitor (CGM). The discreet design simplifies the insertion and wear experience, eliminating the need for overtape.

Insulin pumps and insulin pens are widely used to manage insulin-dependent diabetes, particularly for Type 1 diabetes patients. Insulin pens, more affordable and portable than pumps, have become essential for diabetes management, leading to steady growth in their adoption. Thus, major and emerging players are focussing on the development of advanced insulin pumps. For instance, in September 2024, Modular Medical, Inc. received U. S. Food and Drug Administration clearance to market and sell its MODD1 pump in the United States.

The integration of technology into diabetes care devices has made the market players develop more user-friendly and efficient devices, increasing their market dominance. For instance, in October 2024, Ascensia Diabetes Care launched the Eversense 365 continuous glucose monitoring (CGM) system, the world's only One Year CGM, for people with diabetes in the U.S. Developed by Senseonics Holdings, Inc., Eversense 365 is the only CGM that provides one year of accurate monitoring with minimal disruptions, enabling confident decisions, long-term peace of mind, and enhanced quality of life with just one CGM.

Geographical Analysis

North America is expected to hold a significant position in the diabetes care drugs & devices market with highest market share

North America, especially the United States, has one of the highest diabetes rates globally, significantly driving the demand for diabetes care products. For instance, according to the Centers for Disease Control and Prevention (CDC), in the U.S., approximately 38.4 million people of all ages (about 11.6% of the population) have diabetes. This high prevalence fuels both the demand for diabetes drugs such as insulin and oral medications and advanced monitoring and delivery devices such as CGMs and insulin pumps.

North America particularly the United States and Canada is home to some of the major leading companies in the diabetes care market, including Medtronic, Abbott Laboratories, Dexcom, Roche, Merck & Co., Inc. and Novo Nordisk. These companies significantly influence market trends by innovative product launches, drive innovations and contribute to the availability and distribution of cutting-edge diabetes care drugs and devices.

For instance, in June 2024, Abbott's world-leading FreeStyle Libre portfolio of continuous glucose monitors has revolutionized the way roughly 6 million people worldwide manage their diabetes. The FDA also cleared Libre Rio, Abbott's first over-the-counter CGM system for people with diabetes in the United States. Libre Rio is designed for people ages 18 years and older with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.

Asia-Pacific is growing at the fastest pace in the diabetes care drugs & devices market

The Asia-Pacific region is witnessing a significant rise in diabetes cases due to changing lifestyles, urbanization and an aging population. For instance, the International Diabetes Federation (IDF) reports that by 2045, over 200 million people in the APAC region are projected to have diabetes, making it the region with the highest number of diabetes cases globally. Countries like China, India, Japan and Indonesia are experiencing rapid increases in diabetes prevalence due to urbanization and growing health risk factors like obesity and sedentary lifestyles.

As the number of diabetic patients rises, the demand for both diabetes care drugs and diabetes devices is expanding along with advancements in diabetes care devices and drugs, which helps market players to develop advanced drugs and devices. For instance, in April 2024, Sanofi India Limited launched a new diabetes drug Soliqua after receiving marketing authorization from the Central Drugs Standard Control Organisation (CDSCO), indicated as a treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise.

Additionally, in November 2024, Beurer India Pvt. Ltd. officially launched the GL 22 Blood Glucose Monitor. The GL 22 Blood Glucose Monitor combines German precision with advanced technology designed to meet local needs. The device features comprehensive monitoring capabilities, including average readings for 7, 14, 30 and 90 days, offering crucial insights into blood glucose trends. These features closely align with HbA1c levels, a critical marker for long-term blood sugar control, ensuring users and healthcare providers can manage diabetes more effectively.

Competitive Landscape

The major global players in the diabetes care drugs & devices market include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Medtronic plc, Terumo Corporation, B. Braun SE, Merck & Co., Inc., Novo Nordisk A/S., Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Insulet Corporation and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global diabetes care drugs & devices market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Diabetes
      • 3.1.1.2. Rising Advancements in Diabetes Devices
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Diabetes Care Devices
      • 3.1.2.2. Side Effects Associated with Diabetes Drugs
    • 3.1.3. Opportunity
      • 3.1.3.1. Advancements in Diabetes Wearables and Apps
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders
  • 4.15. Pipeline Analysis

5. Diabetes Care Drugs & Devices Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Diabetes Devices*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Blood Glucose Monitoring Devices
      • 5.2.3.1. Continuous Glucose Monitoring Devices
      • 5.2.3.2. Self-Monitoring Devices
      • 5.2.3.2.1. Blood Glucose Meters
      • 5.2.3.2.2. Testing Strips
      • 5.2.3.2.3. Lancets
    • 5.2.4. Insulin Delivery Devices
      • 5.2.4.1. Insulin Pumps
      • 5.2.4.2. Insulin Pens
      • 5.2.4.3. Insulin Syringes
      • 5.2.4.4. Others
  • 5.3. Diabetes Drugs
    • 5.3.1. Insulin
      • 5.3.1.1. Slow-acting Insulin
      • 5.3.1.2. Intermediate-acting Insulin
      • 5.3.1.3. Fast-acting Insulin
      • 5.3.1.4. Others
    • 5.3.2. Oral Anti-Diabetic Drugs
      • 5.3.2.1. Biguanides
      • 5.3.2.2. Sulfonylureas
      • 5.3.2.3. Thiazolidinediones
      • 5.3.2.4. Alpha-Glucosidase Inhibitors
      • 5.3.2.5. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
      • 5.3.2.6. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
      • 5.3.2.7. Others
    • 5.3.3. Non-Insulin Injectable Drugs
      • 5.3.3.1. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
      • 5.3.3.2. Amylin Analogues
    • 5.3.4. Combination Drugs
    • 5.3.5. Others

6. Diabetes Care Drugs & Devices Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Type-1 Diabetes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Type-2 Diabetes
  • 6.4. Gestational Diabetes
  • 6.5. Prediabetes

7. Diabetes Care Drugs & Devices Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Homecare Settings
  • 7.5. Diagnostic Centers
  • 7.6. Others

8. Diabetes Care Drugs & Devices Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. F. Hoffmann-La Roche Ltd.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Abbott Laboratories
  • 10.3. Medtronic plc
  • 10.4. Terumo Corporation
  • 10.5. B. Braun SE
  • 10.6. Merck & Co., Inc.
  • 10.7. Novo Nordisk A/S.
  • 10.8. Eli Lilly and Company
  • 10.9. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 10.10. Insulet Corporation

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us